Jump to content

Nita Ahuja: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
format refs
Citation bot (talk | contribs)
Added publisher. | Use this bot. Report bugs. | Suggested by Abductive | Category:Indian emigrants to the United States | #UCB_Category 153/907
 
(39 intermediate revisions by 19 users not shown)
Line 1: Line 1:
{{Short description|Surgeon}}
{{lr|date=March 2018}}
'''Nita Ahuja''' MD, MBA is the Chairperson and Surgeon in-chief of the Department of Surgery at Yale New Haven Hospital.<ref>[https://medicine.yale.edu/news/article.aspx?id=16196/]{{dead link|date=March 2018}}</ref> She is the first woman ever to be the Chair of Surgery Department in more than 200 year history of the Yale New Haven Hospital.<ref>{{cite web |url=https://twitter.com/YaleSurgery/status/931156918793592833/ |title=Message|website=twitter.com}}</ref> Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at [[Johns Hopkins Hospital]], [[Baltimore, USA]]. <ref name="JHU">{{cite web|title=Nita Ahuja M.D.|url=http://www.hopkinsmedicine.org/profiles/results/directory/profile/0006948/nita-ahuja|website=HopkinsMedicine.org|publisher=Johns Hopkins School of Medicine|accessdate=23 April 2017}}</ref> Dr. Ahuja researches in the field of [[epigenetics]]. She also served as the director of [[Sarcoma]] and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.<ref>{{cite web |url=https://www.researchgate.net/profile/Nita_Ahuja/ |title=Bio |website=researchgate.net}}</ref>
'''Nita Ahuja''' is a [[surgeon]] and the Chair of the Department of Surgery at [[Yale School of Medicine]] and Surgeon-in-Chief of Surgery at [[Yale New Haven Hospital]].<ref>{{cite news|url=https://medicine.yale.edu/news-article/16196/|title=Nita Ahuja Named Chair of Surgery|date=16 November 2017|accessdate=5 September 2019}}</ref><ref>{{Cite web|title=Nita Ahuja > Doctor at Yale Medicine|url=https://www.yalemedicine.org/doctors/nita_ahuja/|access-date=2020-07-22|website=Yale Medicine|language=en}}</ref> She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at [[Johns Hopkins Hospital]], [[Baltimore, USA]].<ref name="JHU">{{cite web|title=Nita Ahuja M.D.|url=http://www.hopkinsmedicine.org/profiles/results/directory/profile/0006948/nita-ahuja|website=HopkinsMedicine.org|publisher=Johns Hopkins School of Medicine|accessdate=23 April 2017}}</ref> Ahuja researches in the field of [[epigenetics]] and is a passionate advocate of clinician scientist.<ref>{{Cite web |title=Nita Ahuja, MD, MBA, FACS |url=https://medicine.yale.edu/profile/nita_ahuja/ |access-date=2022-04-14 |website=medicine.yale.edu |language=en}}</ref> She also served as the director of [[Sarcoma]] and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.<ref>{{Cite web|title=Nita Ahuja, MD, MBA, FACS|url=https://medicine.yale.edu/ysm/profile/nita_ahuja/|access-date=2020-07-22|website=Yale School of Medicine|language=en}}</ref>


==Early life and education==
Born in India, she migrated to the United States in early childhood with her parents. Her journey into the world of science started as a laboratory technician in Dept. of Immunology, National Institute of Health (NIH), Bethesda. She was awarded with "Outstanding College Students of America" and "Alpha-omega-alpha original research award" for her outstanding research work. She joined the faculty of Johns Hopkins in 2003 after studying medicine at [[Duke University]] and surgery at Johns Hopkins.<ref name="JHU" />
Born in [[India]], she migrated to the United States with her parents when she was 8 years old.<ref>{{Cite web |title=A New Direction for Surgery |url=https://www.yalemedicine.org/news/nita-ahuja-surgery |access-date=2022-05-16 |website=Yale Medicine |language=en}}</ref> Her journey into the world of science started as a laboratory technician in Dept. of Immunology, [[National Institutes of Health]] (NIH), Bethesda. She was awarded with "Outstanding College Students of America" and "Alpha-omega-alpha original research award" for her outstanding research work. She joined the faculty of Johns Hopkins in 2003 after studying medicine at [[Duke University]] and surgery at Johns Hopkins.<ref name="JHU"/>


==Career==
Dr. Ahuja runs a research laboratory focused on understanding the epigenetic dysregulation in gastrointestinal cancers such as colorectal cancers and pancreas cancers and translating the information to develop biomarkers and epigenetic therapeutics.<ref>{{cite web|url=https://www.facebook.com/Ahuja-Lab-Johns-Hopkins-Medical-Institutes-1164131003706003/|title=Ahuja Lab, Johns Hopkins Medical Institutes|website=www.facebook.com}}</ref> Her work initially as a postdoctoral research fellow twenty years ago identified the concept of [[CpG island]] methylator phenotype (CIMP) or [[CpG island hypermethylation]] in colorectal cancer.<ref>{{cite journal | pmid = 10411935 | volume=96 | title=CpG island methylator phenotype in colorectal cancer | pmc=17576 | date=July 1999 | journal=Proc. Natl. Acad. Sci. U.S.A. | pages=8681–6 | last1 = Toyota | first1 = M | last2 = Ahuja | first2 = N | last3 = Ohe-Toyota | first3 = M | last4 = Herman | first4 = JG | last5 = Baylin | first5 = SB | last6 = Issa | first6 = JP | doi=10.1073/pnas.96.15.8681}}</ref> This concept of CIMP now is known to have implications for prognosis as well as response to therapy. CIMP has now been shown to exist in multiple other tumor types such as glioblastomas, leukemia, duodenal cancers etc. Her laboratory has also identified biomarkers for early detection of colorectal and pancreas cancer using non-invasive body fluids such as serum or plasma.<ref name="Yi et al 2013">{{cite journal|last1=Yi|first1=JM|last2=Guzzetta|first2=AA|last3=Bailey|first3=VJ|last4=Downing|first4=SR|last5=Van Neste|first5=L|last6=Chiappinelli|first6=KB|last7=Keeley|first7=BP|last8=Stark|first8=A|last9=Herrera|first9=A|last10=Wolfgang|first10=C|last11=Pappou|first11=EP|last12=Iacobuzio-Donahue|first12=CA|last13=Goggins|first13=MG|last14=Herman|first14=JG|last15=Wang|first15=TH|last16=Baylin|first16=SB|last17=Ahuja|first17=N|title=Novel methylation biomarker panel for the early detection of pancreatic cancer.|journal=Clinical Cancer Research |date=1 December 2013|volume=19|issue=23|pages=6544–55|pmid=24088737|pmc=4310572|doi=10.1158/1078-0432.CCR-12-3224}}</ref> These biomarkers have been licensed and are currently being developed into a commercial assay. Dr. Ahuja also led the epigenetic therapy trials in solid tumors as part of the Stand Up To Cancer consortium since 2008 and since then her laboratory has generated preclinical data for the next generation of clinical epigenetic trials conducted nationally and internationally.<ref>{{cite journal | pmid = 28186961 | doi=10.18632/oncotarget.15108 | volume=8 | title=Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study | journal=Oncotarget | pages=35326–35338 | last1 = Azad | first1 = NS | last2 = El-Khoueiry | first2 = A | last3 = Yin | first3 = J | last4 = Oberg | first4 = AL | last5 = Flynn | first5 = P | last6 = Adkins | first6 = D | last7 = Sharma | first7 = A | last8 = Weisenberger | first8 = DJ | last9 = Brown | first9 = T | last10 = Medvari | first10 = P | last11 = Jones | first11 = PA | last12 = Easwaran | first12 = H | last13 = Kamel | first13 = I | last14 = Bahary | first14 = N | last15 = Kim | first15 = G | last16 = Picus | first16 = J | last17 = Pitot | first17 = HC | last18 = Erlichman | first18 = C | last19 = Donehower | first19 = R | last20 = Shen | first20 = H | last21 = Laird | first21 = PW | last22 = Piekarz | first22 = R | last23 = Baylin | first23 = S | last24 = Ahuja | first24 = N}}</ref><ref>{{cite journal | pmid = 27979916 | doi=10.1158/1078-0432.CCR-16-1729 | volume=23 | title=Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study | pmc=5457329 | journal=Clin Cancer Res | pages=2691–2701 | last1 = Connolly | first1 = RM | last2 = Li | first2 = H | last3 = Jankowitz | first3 = RC | last4 = Zhang | first4 = Z | last5 = Rudek | first5 = MA | last6 = Jeter | first6 = SC | last7 = Slater | first7 = SA | last8 = Powers | first8 = P | last9 = Wolff | first9 = AC | last10 = Fetting | first10 = JH | last11 = Brufsky | first11 = A | last12 = Piekarz | first12 = R | last13 = Ahuja | first13 = N | last14 = Laird | first14 = PW | last15 = Shen | first15 = H | last16 = Weisenberger | first16 = DJ | last17 = Cope | first17 = L | last18 = Herman | first18 = JG | last19 = Somlo | first19 = G | last20 = Garcia | first20 = AA | last21 = Jones | first21 = PA | last22 = Baylin | first22 = SB | last23 = Davidson | first23 = NE | last24 = Zahnow | first24 = CA | last25 = Stearns | first25 = V}}</ref> She is co-author of a 2016 report for the Society of University Surgeons on barriers facing surgeon-scientists in basic science,<ref name="Keswani 2016">{{cite journal|last1=Keswani|first1=SG|last2=Moles|first2=CM|last3=Morowitz|first3=M|last4=Zeh|first4=H|last5=Kuo|first5=JS|last6=Levine|first6=MH|last7=Cheng|first7=LS|last8=Hackam|first8=DJ|last9=Ahuja|first9=N|last10=Goldstein|first10=AM|last11=Basic Science Committee of the Society of University|first11=Surgeons.|title=The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists.|journal=Annals of Surgery|date=16 September 2016|pmid=27643928|accessdate=|doi=10.1097/SLA.0000000000002009|volume=265|pmc=5450912|pages=1053–1059}}</ref> as well as Johns Hopkins guides for patients, including on pancreatic cancer.<ref name="JH Pancreatic Cancer">{{cite book|last1=Ahuja|first1=Nita|last2=Coleman|first2=JoAnn|title=Johns Hopkins Patients' Guide to Pancreatic Cancer|date=2010|publisher=Jones & Bartlett Learning|isbn=9781449632762|url=https://books.google.com/books?id=Qo0myMPj3IMC&dq=Johns+Hopkins+Patients%27+Guide+To+Pancreatic+Cancer+(Johns+Hopkins+Medicine)&source=gbs_navlinks_s|accessdate=23 April 2017|language=en}}</ref>
Ahuja runs a research laboratory focused on understanding the epigenetic dysregulation in gastrointestinal cancers such as colorectal cancers and pancreas cancers and translating the information to develop biomarkers and epigenetic therapeutics.<ref>{{Cite web|last1=Ahuja|first1=Nita|last2=Easwaran|first2=Hariharan|last3=Iacobuzio-Donahue|first3=Christine|title=(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer|url=https://grantome.com/grant/NIH/R01-CA185357-01|language=en}}</ref> She has led over twenty national and international clinical trials on testing new therapies in gastrointestinal and breast cancers based on concepts identified in her laboratory.<ref>{{Cite web |title=Nita Ahuja, MD, MBA, FACS |url=https://medicine.yale.edu/profile/nita_ahuja/ |access-date=2022-04-18 |website=medicine.yale.edu |language=en}}</ref> Her work initially as a postdoctoral research fellow twenty years ago identified the concept of [[CpG island]] methylator phenotype (CIMP) or [[CpG island hypermethylation]] in colorectal cancer.<ref>{{cite journal|pmid=10411935|volume=96|title=CpG island methylator phenotype in colorectal cancer|pmc=17576|date=July 1999|journal=Proc. Natl. Acad. Sci. U.S.A.|pages=8681–6|author1=Toyota, M.|author2=Ahuja, N.|author3=Ohe-Toyota, M.|author4=Herman, J.G.|author4-link=James G. Herman|author5=Baylin, S.B.|author5-link=Stephen B. Baylin|author6=Issa, J.P.|issue=15|doi=10.1073/pnas.96.15.8681|bibcode=1999PNAS...96.8681T|doi-access=free}}</ref> This concept of CIMP now is known to have implications for prognosis as well as response to therapy.<ref>{{Cite web|last=Ahuja|first=Nita|title=Epigenetic markers involved in colorectal cancer recurrence and metastases|url=https://grantome.com/grant/NIH/K23-CA127141-04|language=en}}</ref> CIMP has now been shown to exist in multiple other tumor types such as glioblastomas, leukemia, duodenal cancers etc.<ref>{{Cite web|title=Nita Ahuja, MD, MBA - Google Scholar|url=https://scholar.google.com/citations?user=4FjV37cAAAAJ&hl=en|access-date=2020-07-22|website=scholar.google.com}}</ref><ref>{{Cite web|title=Dr. Nita Ahuja, MD – New Haven, CT {{!}} General Surgery on Doximity|url=https://www.doximity.com/pub/nita-ahuja-md|access-date=2020-07-22|website=Doximity}}</ref>

Her laboratory has also identified biomarkers for early detection of colorectal and pancreas cancer using non-invasive body fluids such as serum or plasma.<ref>{{cite journal|author1=Yi, J.M.|author2=Guzzetta, A.A.|author3=Bailey, V.J.|author4=Downing, S.R.|author5=Van Neste, L.|author6=Chiappinelli, K.B.|author7=Keeley, B.P.|author8=Stark, A.|author9=Herrera, A.|author10=Wolfgang, C.|author11=Pappou, E.P.|author12=Iacobuzio-Donahue, C.A.|author13=Goggins, M.G.|author14=Herman, J.G.|author15=Wang, T.H.|author16=Baylin, S.B.|author17=Ahuja, N.|title=Novel methylation biomarker panel for the early detection of pancreatic cancer.|journal=Clinical Cancer Research|date=1 December 2013|volume=19|issue=23|pages=6544–55|pmid=24088737|pmc=4310572|doi=10.1158/1078-0432.CCR-12-3224}}</ref> These biomarkers have been licensed and are currently being developed into a commercial assay.<ref>{{Cite web|title=Hey Siri Should I Get a Medical Degree - The ASCO Post|url=https://www.ascopost.com/issues/september-10-2019/hey-siri-should-i-get-a-medical-degree/|access-date=2020-07-22|website=www.ascopost.com}}</ref>

Ahuja also led the epigenetic therapy trials in solid tumors as part of the Stand Up To Cancer consortium since 2008 and since then her laboratory has generated preclinical data for the next generation of clinical epigenetic trials conducted nationally and internationally.<ref>{{cite journal|pmid=28186961|doi=10.18632/oncotarget.15108|volume=8|title=Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study|journal=Oncotarget|pages=35326–35338|author1=Azad, N.S.|author2=El-Khoueiry, A.|author3=Yin, J.|author4=Oberg, A.L.|author5=Flynn, P.|author6=Adkins, D.|author7=Sharma, A.|author8=Weisenberger, D.J.|author9=Brown, T.|author10=Medvari, P.|author11=Jones, P.A.|author12=Easwaran, H.|author13=Kamel, I.|author14=Bahary, N.|author15=Kim, G.|author16=Picus, J.|author17=Pitot, H.C.|author18=Erlichman, C.|author19=Donehower, R.|author20=Shen, H.|author21=Laird, P.W.|author22=Piekarz, R.|author23=Baylin, S.|author24=Ahuja, N.|year=2017|issue=21|pmc=5471058}}</ref><ref>{{cite journal|pmid=27979916|doi=10.1158/1078-0432.CCR-16-1729|volume=23|title=Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study|pmc=5457329|journal=Clin Cancer Res|pages=2691–2701|author1=Connolly, R.M.|author2=Li, H.|author3=Jankowitz, R.C.|author4=Zhang, Z.|author5=Rudek, M.A.|author6=Jeter, S.C.|author7=Slater, S.A.|author8=Powers, P.|author9=Wolff, A.C.|author10=Fetting, J.H.|author11=Brufsky, A.|author12=Piekarz, R.|author13=Ahuja, N.|author14=Laird, P.W.|author15=Shen, H.|author16=Weisenberger, D.J.|author17=Cope, L.|author18=Herman, J.G.|author19=Somlo, G.|author20=Garcia, A.A.|author21=Jones, P.A.|author22=Baylin, S.B.|author23=Davidson, N.E.|author24=Zahnow, C.A.|author25=Stearns, V.|year=2017|issue=11}}</ref> She has won several awards over the years including the Abell Foundation Award: Johns Hopkins Alliance for Science and Technology Development in 2014.<ref>{{Cite web |title=Nita Ahuja, MD, MBA, FACS |url=https://medicine.yale.edu/profile/nita_ahuja/ |access-date=2022-05-16 |website=medicine.yale.edu |language=en}}</ref>

== Writing ==
She is co-author of a 2016 report for the Society of University Surgeons on barriers facing surgeon-scientists in basic science.<ref>{{cite journal|author1=Keswani, S.G.|author2=Moles, C.M.|author3=Morowitz, M.|author4=Zeh, H.|author5=Kuo, J.S.|author6=Levine, M.H.|author7=Cheng, L.S.|author8=Hackam, D.J.|author9=Ahuja, N.|author10=Goldstein, A.M.|publisher=Basic Science Committee of the Society of University Surgeons|title=The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists.|journal=Annals of Surgery|year=2016|pmid=27643928|doi=10.1097/SLA.0000000000002009|volume=265|issue=6|pmc=5450912|pages=1053–1059}}</ref> She also co-authored Along with ''Soft Tissue Sarcomas, An Issue of Surgical Clinics (Volume 88-3) (The Clinics: Surgery (Volume 88-3)).''<ref>{{Cite book|isbn=978-1416058052|title=Soft Tissue Sarcomas|last1=Hueman|first1=Matthew T.|last2=Ahuja|first2=Nita|year=2008}}</ref>

As well as Johns Hopkins guides for patients, including:

* ''Johns Hopkins Patients' Guide to Pancreatic Cance''r<ref>{{cite book|author=Ahuja, Nita|author2=Coleman, JoAnn|title=Johns Hopkins Patients' Guide to Pancreatic Cancer|year=2010|publisher=Jones & Bartlett Learning|isbn=9781449632762}}</ref><ref>{{Cite book|isbn=978-0763774585|title=Johns Hopkins Patients' Guide to Pancreatic Cancer|last1=Ahuja|first1=Nita|last2=Coleman|first2=Joann|date=22 December 2010|publisher=Jones & Bartlett Learning }}</ref>
* ''Johns Hopkins Patient Guide to Colon and Rectal Cancer'',<ref>{{Cite book|url=https://www.amazon.com/Hopkins-Patient-Rectal-Cancer-Patients-ebook/dp/B00C7UP8DA/ref=sr_1_2?dchild=1&qid=1595428210&refinements=p_27:Nita+Ahuja&s=books&sr=1-2|access-date=2020-07-22|via=www.amazon.com|title=Johns Hopkins Patient Guide to Colon and Rectal Cancer|date=7 March 2013|publisher=Jones & Bartlett Learning }}</ref>
* ''Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult (Early Diagnosis in Cancer)''.<ref>{{Cite book|url=https://www.amazon.com/Early-Diagnosis-Treatment-Cancer-Colorectal-ebook/dp/B005410Q8G/ref=sr_1_3?dchild=1&qid=1595428210&refinements=p_27:Nita+Ahuja&s=books&sr=1-3|access-date=2020-07-22|via=www.amazon.com|title=Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult|date=15 July 2010|publisher=Saunders }}</ref>


==References==
==References==
{{reflist|30em}}
{{Reflist|30em}}


{{Authority control}}
{{Authority control}}
Line 15: Line 30:
[[Category:Living people]]
[[Category:Living people]]
[[Category:Women geneticists]]
[[Category:Women geneticists]]
[[Category:Duke University alumni]]
[[Category:Indian emigrants to the United States]]
[[Category:Indian emigrants to the United States]]
[[Category:Johns Hopkins Hospital physicians]]
[[Category:Johns Hopkins Hospital physicians]]
[[Category:Duke University School of Medicine alumni]]
[[Category:Duke University School of Medicine alumni]]
[[Category:21st-century women scientists]]
[[Category:21st-century American women scientists]]
[[Category:American women scientists of Indian descent]]
[[Category:Members of the National Academy of Medicine]]

Latest revision as of 12:57, 30 September 2024

Nita Ahuja is a surgeon and the Chair of the Department of Surgery at Yale School of Medicine and Surgeon-in-Chief of Surgery at Yale New Haven Hospital.[1][2] She is the first woman ever to serve as Chair of Surgery in Yale in its >200 year history. Before taking this position she was the first woman ever to be the Chief of Surgical Oncology at Johns Hopkins Hospital, Baltimore, USA.[3] Ahuja researches in the field of epigenetics and is a passionate advocate of clinician scientist.[4] She also served as the director of Sarcoma and peritoneal surface malignancy program. She is a surgeon-scientist and her research has been cited more than 11,000 times in scientific literature.[5]

Early life and education

[edit]

Born in India, she migrated to the United States with her parents when she was 8 years old.[6] Her journey into the world of science started as a laboratory technician in Dept. of Immunology, National Institutes of Health (NIH), Bethesda. She was awarded with "Outstanding College Students of America" and "Alpha-omega-alpha original research award" for her outstanding research work. She joined the faculty of Johns Hopkins in 2003 after studying medicine at Duke University and surgery at Johns Hopkins.[3]

Career

[edit]

Ahuja runs a research laboratory focused on understanding the epigenetic dysregulation in gastrointestinal cancers such as colorectal cancers and pancreas cancers and translating the information to develop biomarkers and epigenetic therapeutics.[7] She has led over twenty national and international clinical trials on testing new therapies in gastrointestinal and breast cancers based on concepts identified in her laboratory.[8] Her work initially as a postdoctoral research fellow twenty years ago identified the concept of CpG island methylator phenotype (CIMP) or CpG island hypermethylation in colorectal cancer.[9] This concept of CIMP now is known to have implications for prognosis as well as response to therapy.[10] CIMP has now been shown to exist in multiple other tumor types such as glioblastomas, leukemia, duodenal cancers etc.[11][12]

Her laboratory has also identified biomarkers for early detection of colorectal and pancreas cancer using non-invasive body fluids such as serum or plasma.[13] These biomarkers have been licensed and are currently being developed into a commercial assay.[14]

Ahuja also led the epigenetic therapy trials in solid tumors as part of the Stand Up To Cancer consortium since 2008 and since then her laboratory has generated preclinical data for the next generation of clinical epigenetic trials conducted nationally and internationally.[15][16] She has won several awards over the years including the Abell Foundation Award: Johns Hopkins Alliance for Science and Technology Development in 2014.[17]

Writing

[edit]

She is co-author of a 2016 report for the Society of University Surgeons on barriers facing surgeon-scientists in basic science.[18] She also co-authored Along with Soft Tissue Sarcomas, An Issue of Surgical Clinics (Volume 88-3) (The Clinics: Surgery (Volume 88-3)).[19]

As well as Johns Hopkins guides for patients, including:

  • Johns Hopkins Patients' Guide to Pancreatic Cancer[20][21]
  • Johns Hopkins Patient Guide to Colon and Rectal Cancer,[22]
  • Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult (Early Diagnosis in Cancer).[23]

References

[edit]
  1. ^ "Nita Ahuja Named Chair of Surgery". 16 November 2017. Retrieved 5 September 2019.
  2. ^ "Nita Ahuja > Doctor at Yale Medicine". Yale Medicine. Retrieved 2020-07-22.
  3. ^ a b "Nita Ahuja M.D." HopkinsMedicine.org. Johns Hopkins School of Medicine. Retrieved 23 April 2017.
  4. ^ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-04-14.
  5. ^ "Nita Ahuja, MD, MBA, FACS". Yale School of Medicine. Retrieved 2020-07-22.
  6. ^ "A New Direction for Surgery". Yale Medicine. Retrieved 2022-05-16.
  7. ^ Ahuja, Nita; Easwaran, Hariharan; Iacobuzio-Donahue, Christine. "(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer".
  8. ^ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-04-18.
  9. ^ Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.P. (July 1999). "CpG island methylator phenotype in colorectal cancer". Proc. Natl. Acad. Sci. U.S.A. 96 (15): 8681–6. Bibcode:1999PNAS...96.8681T. doi:10.1073/pnas.96.15.8681. PMC 17576. PMID 10411935.
  10. ^ Ahuja, Nita. "Epigenetic markers involved in colorectal cancer recurrence and metastases".
  11. ^ "Nita Ahuja, MD, MBA - Google Scholar". scholar.google.com. Retrieved 2020-07-22.
  12. ^ "Dr. Nita Ahuja, MD – New Haven, CT | General Surgery on Doximity". Doximity. Retrieved 2020-07-22.
  13. ^ Yi, J.M.; Guzzetta, A.A.; Bailey, V.J.; Downing, S.R.; Van Neste, L.; Chiappinelli, K.B.; Keeley, B.P.; Stark, A.; Herrera, A.; Wolfgang, C.; Pappou, E.P.; Iacobuzio-Donahue, C.A.; Goggins, M.G.; Herman, J.G.; Wang, T.H.; Baylin, S.B.; Ahuja, N. (1 December 2013). "Novel methylation biomarker panel for the early detection of pancreatic cancer". Clinical Cancer Research. 19 (23): 6544–55. doi:10.1158/1078-0432.CCR-12-3224. PMC 4310572. PMID 24088737.
  14. ^ "Hey Siri Should I Get a Medical Degree - The ASCO Post". www.ascopost.com. Retrieved 2020-07-22.
  15. ^ Azad, N.S.; El-Khoueiry, A.; Yin, J.; Oberg, A.L.; Flynn, P.; Adkins, D.; Sharma, A.; Weisenberger, D.J.; Brown, T.; Medvari, P.; Jones, P.A.; Easwaran, H.; Kamel, I.; Bahary, N.; Kim, G.; Picus, J.; Pitot, H.C.; Erlichman, C.; Donehower, R.; Shen, H.; Laird, P.W.; Piekarz, R.; Baylin, S.; Ahuja, N. (2017). "Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study". Oncotarget. 8 (21): 35326–35338. doi:10.18632/oncotarget.15108. PMC 5471058. PMID 28186961.
  16. ^ Connolly, R.M.; Li, H.; Jankowitz, R.C.; Zhang, Z.; Rudek, M.A.; Jeter, S.C.; Slater, S.A.; Powers, P.; Wolff, A.C.; Fetting, J.H.; Brufsky, A.; Piekarz, R.; Ahuja, N.; Laird, P.W.; Shen, H.; Weisenberger, D.J.; Cope, L.; Herman, J.G.; Somlo, G.; Garcia, A.A.; Jones, P.A.; Baylin, S.B.; Davidson, N.E.; Zahnow, C.A.; Stearns, V. (2017). "Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study". Clin Cancer Res. 23 (11): 2691–2701. doi:10.1158/1078-0432.CCR-16-1729. PMC 5457329. PMID 27979916.
  17. ^ "Nita Ahuja, MD, MBA, FACS". medicine.yale.edu. Retrieved 2022-05-16.
  18. ^ Keswani, S.G.; Moles, C.M.; Morowitz, M.; Zeh, H.; Kuo, J.S.; Levine, M.H.; Cheng, L.S.; Hackam, D.J.; Ahuja, N.; Goldstein, A.M. (2016). "The Future of Basic Science in Academic Surgery: Identifying Barriers to Success for Surgeon-scientists". Annals of Surgery. 265 (6). Basic Science Committee of the Society of University Surgeons: 1053–1059. doi:10.1097/SLA.0000000000002009. PMC 5450912. PMID 27643928.
  19. ^ Hueman, Matthew T.; Ahuja, Nita (2008). Soft Tissue Sarcomas. ISBN 978-1416058052.
  20. ^ Ahuja, Nita; Coleman, JoAnn (2010). Johns Hopkins Patients' Guide to Pancreatic Cancer. Jones & Bartlett Learning. ISBN 9781449632762.
  21. ^ Ahuja, Nita; Coleman, Joann (22 December 2010). Johns Hopkins Patients' Guide to Pancreatic Cancer. Jones & Bartlett Learning. ISBN 978-0763774585.
  22. ^ Johns Hopkins Patient Guide to Colon and Rectal Cancer. Jones & Bartlett Learning. 7 March 2013. Retrieved 2020-07-22 – via www.amazon.com.
  23. ^ Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer: Expert Consult. Saunders. 15 July 2010. Retrieved 2020-07-22 – via www.amazon.com.